Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation

OBJECTIVES: The aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes. METHODS: We identified people with viruses harbouring the M184V/I mutation in UK multicentre data sets who had treatm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:HIV Med
Autors principals: Stirrup, OT, Asboe, D, Pozniak, A, Sabin, CA, Gilson, R, Mackie, NE, Tostevin, A, Hill, T, Dunn, DT
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217157/
https://ncbi.nlm.nih.gov/pubmed/31927793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hiv.12829
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars